Home page  | Editorial   | Journal  |  Guidelines to authors |  Contact  | |  

Acta Medica Medianae
Vol. 46, No 2, April, 2007
UDK 61
YU ISSN 0365-4478



Correspondence to:
Predrag Stojanović

Medicinski fakultet

Bulevar dr Zorana Đinđića 81

18000 Niš, Srbija

Tel.: 018/326384





Copyright 2007 by Faculty  of Medicine, University of Nis



Predrag Stojanovic , Branislava Kocic, Gordana Randjelovic, Dobrila Stankovic-Djordjevic, Biljana Miljkovic-Selimovic, Snezana Antic-Mladenovic, Kristina Stojanovic and Tatjana Babic


Faculty of Medicine in Nis*
Public Health Institute in Nis **
Clinical Center in Nis***

Clostridium difficile is a Gram-positive, spore-forming, anaerobic bacillus that is widely distributed in the environment, but is found as a part of a normal large bowel flora in approximately 3% of normal adults. C. difficile produces two protein exotoxins: toxin A and toxin B. Both toxins are responsible for causing the sings and symptoms of disease.

C. difficile is now thought to be responsible for a spectrum of diseases, ranging from asymptomatic colonization to diarrhea of varying severity, life-threatening colitis, often as a consequence of long-term antibiotic exposure. This spectrum has become known as C. difficile-associated disease (CDAD).

Treatment of Clostridium difficile-associated disease demand administration of effi-cient antibiotics (vancomycin, metronidazole), anion exchange resins and probiotics (Lactobacillus spp., Saccharomyces boulardii). Acta Medica Medianae 2007;46(2):31-36.


Key words: Clostridium difficile, CDAD, treatment

Fulll text